首页> 外文期刊>The Journal of Nuclear Medicine >Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
【24h】

Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

机译:肺癌中18F-氟代咪唑和3'-脱氧-3'-18F-氟胸苷PET图像的定性分析和肿瘤描绘的观察者同意。

获取原文
获取原文并翻译 | 示例
           

摘要

As the preparation phase of a multicenter clinical trial using (18)F-fluoro-2-deoxy-d-glucose ((18)F-FDG), (18)F-fluoromisonidazole ((18)F-FMISO), and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in non-small cell lung cancer (NSCLC) patients, we investigated whether 18 nuclear medicine centers would score tracer uptake intensity similarly and define hypoxic and proliferative volumes for 1 patient and we compared different segmentation methods.Ten (18)F-FDG, ten (18)F-FMISO, and ten (18)F-FLT PET/CT examinations were performed before and during curative-intent radiotherapy in 5 patients with NSCLC. The gold standards for uptake intensity and volume delineation were defined by experts. The between-center agreement (18 nuclear medicine departments connected with a dedicated network, SFMN-net [French Society of Nuclear Medicine]) in the scoring of uptake intensity (5-level scale, then divided into 2 levels: 0, normal; 1, abnormal) was quantified by κ-coefficients (κ). The volumes defined by different physicians were compared by overlap and κ. The uptake areas were delineated with 22 different methods of segmentation, based on fixed or adaptive thresholds of standardized uptake value (SUV).For uptake intensity, the κ values between centers were, respectively, 0.59 for (18)F-FDG, 0.43 for (18)F-FMISO, and 0.44 for (18)F-FLT using the 5-level scale; the values were 0.81 for (18)F-FDG and 0.77 for both (18)F-FMISO and (18)F-FLT using the 2-level scale. The mean overlap and mean κ between observers were 0.13 and 0.19, respectively, for (18)F-FMISO and 0.2 and 0.3, respectively, for (18)F-FLT. The segmentation methods yielded significantly different volumes for (18)F-FMISO and (18)F-FLT (P < 0.001). In comparison with physicians, the best method found was 1.5 × maximum SUV (SUVmax) of the aorta for (18)F-FMISO and 1.3 × SUVmax of the muscle for (18)F-FLT. The methods using the SUV of 1.4 and the method using 1.5 × the SUVmax of the aorta could be used for (18)F-FMISO and (18)F-FLT. Moreover, for (18)F-FLT, 2 other methods (adaptive threshold based on 1.5 or 1.6 × muscle SUVmax) could be used.The reproducibility of the visual analyses of (18)F-FMISO and (18)F-FLT PET/CT images was demonstrated using a 2-level scale across 18 centers, but the interobserver agreement was low for the (18)F-FMISO and (18)F-FLT volume measurements. Our data support the use of a fixed threshold (1.4) or an adaptive threshold using the aorta background to delineate the volume of increased (18)F-FMISO or (18)F-FLT uptake. With respect to the low tumor-on-background ratio of these tracers, we suggest the use of a fixed threshold (1.4).
机译:作为使用(18)F-氟-2-脱氧-d-葡萄糖((18)F-FDG),(18)F-氟代咪唑((18)F-FMISO)和3的多中心临床试验的准备阶段'-deoxy-3'-(18)F-氟胸苷((18)F-FLT)在非小细胞肺癌(NSCLC)患者中的研究,我们调查了18个核医学中心是否会类似地对示踪剂摄取强度进行评分并定义低氧和1例患者的增生量,我们比较了不同的分割方法。在进行根治性放疗之前和期间,进行了十(18)F-FDG,十(18)F-FMISO和十(18)F-FLT PET / CT检查5例NSCLC患者。吸收强度和体积描绘的金标准是由专家定义的。中心之间的协议(18个核医学科室与专用网络SFMN-net [法国核医学会]连接)在摄取强度的评分上(5级量表,然后分为2级:0,正常; 1) ,异常)通过κ系数(κ)进行量化。通过重叠和κ比较不同医师定义的体积。根据固定或自适应标准摄取值(SUV)阈值,用22种不同的分割方法来划分摄取区域。(18)F-FDG的摄取强度中心之间的κ值分别为0.59、0.43。 (18)F-FMISO,对于(18)F-FLT,使用5级标度为0.44; (18)F-FDG的值为0.81,而(18)F-FMISO和(18)F-FLT的值使用2级量表。对于(18)F-FMISO,观察者之间的平均重叠和平均κ分别为0.13和0.19,对于(18)F-FLT,分别为0.2和0.3。对于(18)F-FMISO和(18)F-FLT,分割方法产生的体积明显不同(P <0.001)。与医生相比,发现的最佳方法是(18)F-FMISO为主动脉的1.5×最大SUV(SUVmax),(18)F-FLT为1.3×肌肉的SUVmax。使用(1.4)SUV的方法和使用1.5×主动脉SUVmax的方法可用于(18)F-FMISO和(18)F-FLT。此外,对于(18)F-FLT,还可以使用其他两种方法(基于1.5或1.6×肌肉SUVmax的自适应阈值)。(18)F-FMISO和(18)F-FLT PET的可视化分析具有可重复性/ CT图像使用18个中心的2级标度进行了演示,但对于(18)F-FMISO和(18)F-FLT体积测量,观察者之间的一致性低。我们的数据支持使用固定阈值(1.4)或使用主动脉背景的自适应阈值来描绘增加的(18)F-FMISO或(18)F-FLT摄取量。关于这些示踪剂的低背景肿瘤比率,我们建议使用固定阈值(1.4)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号